Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
Description
Keywords
Antineoplastic Combined Chemotherapy Protocols , Dexamethasone , Humans , Lenalidomide , Middle Aged , Multiple Myeloma , Retrospective Studies , Turkey , beta 2 microglobulin , dexamethasone , hemoglobin , ixazomib , lactate dehydrogenase , lenalidomide , proteasome inhibitor , antineoplastic agent , dexamethasone , ixazomib , lenalidomide , absolute neutrophil count , adult , adverse event , aged , anemia , Article , atrial fibrillation , bleeding , clinical practice , constipation , creatinine clearance , demographics , diarrhea , disease exacerbation , drug efficacy , drug safety , ECOG Performance Status , female , follow up , glomerulus filtration rate , human , hypertension , International Staging System , laboratory test , line of treatment , liver toxicity , major clinical study , male , middle aged , multicenter study , multiple cycle treatment , multiple myeloma , neutropenia , observational study , overall response rate , platelet count , progression free survival , rash , retrospective study , survival , thrombocytopenia , treatment response , Turkey (republic) , clinical trial , multiple myeloma , turkey (bird)